Key takeaways
- SNAP-8 is a trade name. FDA’s substance registry records its cosmetic ingredient (INCI) name as acetyl octapeptide-3; its sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2.
- It is argireline (acetyl hexapeptide-8, also listed as acetyl hexapeptide-3) with two amino acids, alanine and aspartic acid, added at one end.
- Reviews describe it as competing with SNAP-25 in the SNARE complex, the protein machinery nerve cells use to release messengers; a 2020 review took its lab figures from the manufacturer’s website.
- The two peer-reviewed human studies naming it that we found (2020, 2024) tested microneedle patches that combined it with other active ingredients, so they cannot isolate its contribution.
- In the US, Great Britain and Australia, the product’s claims and intended use decide whether it is a cosmetic; none of the rules we read requires a regulator to check that a cosmetic works before sale.
01SNAP-8 at a glance
The short version, dated 18 November 2026. Every line is sourced at the end of the page.
| Question | SNAP-8 |
|---|---|
| What it is | A trade name for acetyl octapeptide-3: a synthetic peptide of eight amino acids, made as a cosmetic ingredient. |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, capped by an acetyl group at one end and an amide at the other. |
| Formula and mass | C41H70N16O16S; 1075.2 g/mol by PubChem’s calculation (CID 76283482). CAS 868844-74-0. |
| Cosmetic ingredient (INCI) name | Acetyl octapeptide-3, as FDA’s substance registry records it. Also listed as acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3. |
| Relation to argireline | Argireline (INCI acetyl hexapeptide-8, also listed as acetyl hexapeptide-3) is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. SNAP-8 is the same chain with alanine and aspartic acid added. |
| Producer | Lipotec, Barcelona, according to a 2025 review. |
| Evidence tier | T4: laboratory assays; the figures reviews quote come from the manufacturer. T2: two small human studies of multi-ingredient patches. |
| United States | Regulated by intended use. No FDA approval before sale; a claim to affect the body’s structure or function makes a product a drug. |
| Great Britain | UK Cosmetics Regulation: a responsible person, a safety assessment and notification to OPSS before sale. |
| Australia | Cosmetic ingredients can be industrial chemicals, regulated under the Industrial Chemicals Act 2019; a product used for a therapeutic purpose is a therapeutic good. |
| WADA | Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”. See peptides and anti-doping. |
02What is SNAP-8, and how does it relate to argireline?
SNAP-8 is a trade name. The ingredient’s cosmetic name (its INCI name) is acetyl octapeptide-3, which is how FDA’s Global Substance Registration System records it. It is a synthetic chain of eight amino acids: glutamic acid, glutamic acid, methionine, glutamine, arginine, arginine, alanine and aspartic acid. An acetyl group caps one end and an amide the other. The same registry and PubChem also list it as acetyl octapeptide-1 and acetyl glutamyl heptapeptide-3. A 2025 review names Lipotec, in Barcelona, as its producer.
Argireline’s sequence, plus two. Argireline, INCI name acetyl hexapeptide-8 (also listed as acetyl hexapeptide-3), is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. SNAP-8 keeps those six amino acids and adds alanine and aspartic acid. Argireline’s developers described it in 2002 as the product of “a rational design programme” to find “non-toxic molecules that mimic the action of” botulinum neurotoxins. A 2025 review says it was modelled on one end of SNAP-25, a protein nerve cells use to release chemical messengers. More on this family of ingredients: peptides in skincare.
03How is SNAP-8 meant to work?
Nerve cells signal to muscles by releasing chemical messengers stored in small sacs, called vesicles. A group of proteins, the SNARE complex, which includes SNAP-25, docks those vesicles so the messengers can be released.
Reviews describe SNAP-8 as mimicking one end of SNAP-25 and competing with it for a place in the SNARE complex, so that fewer messengers are released. That is a design idea tested in laboratory assays (T4), not a measured effect in people. A 2020 peer-reviewed review gives figures for SNAP-8 in those assays and for wrinkle measurements, and names their source: “the data available in the manufacturer’s website”. We do not repeat those figures. We found no peer-reviewed publication of them (PubMed and Europe PMC, 18 November 2026).
The delivery question. To work this way, a peptide applied to skin has to reach the nerve endings beneath it. For argireline, a 2025 review concluded that “the ability of AH-8 to reach neuromuscular junctions remains uncertain”. We found no published study that measured whether SNAP-8 reaches nerve endings through skin.
04Where does the evidence on SNAP-8 come from?
Every primary source we found came from the company that makes SNAP-8 or involved companies whose products contain it.
| Source | Who produced it | What it tested | What it cannot show |
|---|---|---|---|
| Manufacturer data, as cited in a 2020 review | The producer, on its website (as the review cites it) | Laboratory assays of the SNARE complex and messenger release; wrinkle measurements | Methods, sample sizes and full results are not in the peer-reviewed literature we found |
| Shin et al., 2024 (Annals of Dermatology) | Raphas Co., the patch maker, with the Catholic University of Korea; Raphas supported the study | 24 adults aged 30 to 65: a microneedle patch with acetyl octapeptide-3 and two other active ingredients by one eye, a placebo patch by the other, for 28 days. Measures: wrinkle roughness, skin water loss, elasticity, eye lift, adverse effects | SNAP-8’s share of any change, since the patch had three active ingredients; anything beyond 28 days |
| Avcil et al., 2020 (Journal of Cosmetic Dermatology) | Imperial Bioscience (UK), Dermatest GmbH (Germany) and Raphas Co. (Korea) | A 12-week single-centre study of microneedle patches combining acetyl octapeptide-3 with other peptides, adenosine and seaweed extracts: hydration, wrinkles, skin density and thickness | SNAP-8’s share of any change; the abstract does not give the number of people or say whether there was a control group |
| Reviews (2020 and 2025) | Review authors | Nothing new: they summarise other sources, including the manufacturer’s | Independent confirmation of the manufacturer’s figures |
We searched PubMed and Europe PMC under each of its names and its sequence. Only the two patch studies name it in their title or abstract (18 November 2026), and both include authors from the patch maker. We found no peer-reviewed trial of SNAP-8 on its own. The authors of the 2024 study reported no adverse effects in 24 people over 28 days; a study that size cannot detect uncommon reactions. How we weigh studies like these: evidence grades.
05How do US, UK and Australian cosmetics laws treat SNAP-8?
All three markets decide by the product, not the molecule: what it claims, what form it takes and what it is for.
| Market | What makes it a cosmetic | Before sale | When it is not a cosmetic |
|---|---|---|---|
| United States (FDA) | Intended use. The law defines cosmetics as articles applied to the body “for cleansing, beautifying, promoting attractiveness, or altering the appearance”. | “Cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market.” Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), facilities register, products are listed and serious adverse events are reported to FDA. | A product “intended to affect the structure or any function of the body” is a drug. FDA’s examples of drug claims include promises to “regenerate cells”. |
| Great Britain (UK Cosmetics Regulation) | A substance placed on the external parts of the body mainly to clean, perfume, protect or keep them in good condition, change their appearance or correct body odours (Article 2). | A responsible person with a UK address, a safety assessment, and notification to the Office for Product Safety and Standards (OPSS). The responsible person must “be able to prove that any claims made when marketing the product are correct”. | “A substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product.” For borderline products, the MHRA applies the medicines tests. |
| Australia | The Industrial Chemicals Act 2019 defines a cosmetic by purposes such as cleansing, perfuming, protecting or changing the appearance of an external part of the body, and excludes therapeutic goods. | Cosmetic ingredients can be industrial chemicals, regulated under that Act. | The TGA says a peptide product is a therapeutic good if, for example, it is “promoted, supplied or generally used for a therapeutic purpose”, which includes to “influence, inhibit or modify a physiological process in the body”. |
Two points matter for SNAP-8. Wrinkle care sits inside cosmetics in the UK: the MHRA’s guidance notes that the Regulation’s recital (7) lists “anti-wrinkle products” among cosmetic products, and that the MHRA “only classifies finished products and not individual substances and ingredients”. And the claim decides the category. A product said to act on nerves or muscles is claiming to change how the body works, the kind of claim FDA and the TGA treat as a medicine’s. None of the rules we read requires a regulator to check, before sale, that a cosmetic works. More: what “research use only” means and the skin research area.
06What we don’t know about SNAP-8
- Whether SNAP-8 on its own changes skin in people. We found no peer-reviewed trial of it as a single ingredient.
- Whether it reaches the nerve endings under intact skin. That question is open even for argireline, its shorter parent sequence.
- How the manufacturer’s studies were run: their size, controls and full results are not in the peer-reviewed literature we found.
- What longer use looks like. The two published human studies lasted 28 days and 12 weeks.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.